Drugmaker Deals Are Near Record Pace in 2019, but Investors Don’t Love Them All

A rush of transactions is transforming the industry, as blockbuster medicines lose patent protection. The latest acquisition cost AbbVie 16 percent of its share price. The New York Times By STEPHEN GROCER from NYT Business https://ift.tt/2X6xxKu
Mergers, Acquisitions and Divestitures, Humira (Drug), Drugs (Pharmaceuticals), Inventions and Patents